Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Assay Type | FACS |
Analyte | IL-5 |
Format | 50 tests×2 |
Reactivity | Human |
Regulatory Status | RUO |
Sensitivity | 1.15 pg/mL |
Standard Curve Range | 9.8~5000 pg/mL |
Assay Time | 3 hr |
Suitable Sample Type | Human serum, Human plasma, Cell culture supernatants |
Sample volume | 15 μL |
We offer a range of individual reagents for each factor, giving you the flexibility to select and combine them according to your specific research requirements.
This Panel (Flow Cytometry Bead Assay) gives quantitative results of Interleukin-5 (IL-5) with a sample testing. The performance of this panel has been optimized for specific analysis of cytokines.
It is for research use only.
2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.
3. The shelf life is 30 days from the date of opening.
ID | Components | Size |
FMBc014-02 | Anti-human IL-5 Antibody-coupled APC-beads-C03 | 50 tests |
FABm030-01 | PE labeled Monoclonal Anti-Human IL-5 Antibody, Rat IgG1 | 0.25 mL |
A double logarithmic fitting curve was plotted for IL-10. The present curve of each cytokines was ranging from 9.8 pg/ml to 5000 pg/mL.
A representative scatter plot showing single bead population in P1 gate (left), the beads conjugated with analyte-sepcific antibody differntiated by APC fluorescence intensity (middle), and fluorescence signal in propotion to concentration of the analyte was measured for each cytokine in PE channel (right). Data was generated on Beckman Cytoflex S Flow Cytometer, equipped with blue laser (488 nm) and red laser (640 nm).
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Reslizumab | TRFK-5; CDP-835; SCH-5570; CEP-38072; CTx-55700; SCH-55700 | Approved | Teva Pharmaceutical Industries Ltd | Cinqair, Cinquil, Cinqaero | EU | Asthma | Teva Bv | 2016-03-23 | Loiasis; Hypereosinophilic Syndrome; Pulmonary Eosinophilia; Eosinophilic Esophagitis; Asthma; Bronchitis | Details |
Mepolizumab | SB-240563; 240563 | Approved | Glaxosmithkline Plc | Bosatria, Nucala, 美泊利珠单抗 | EU | Eosinophilic Granuloma; Nasal Polyps; Hypereosinophilic Syndrome; Sinusitis | Glaxosmithkline Trading Services Ltd | 2015-11-04 | Hypereosinophilic Syndrome; Granulomatosis with Polyangiitis; Churg-Strauss Syndrome; Virus Diseases; Nasal Polyps; Chronic Urticaria; Eosinophilia; Eosinophilic Esophagitis; Asthma; Eosinophilic Granuloma; Bronchitis; Sinusitis; Pulmonary Disease, Chronic Obstructive; Fasciitis; Dermatitis, Atopic; Angioedema | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
long-acting anti-IL-5 mAb (GSK) | Phase 1 Clinical | Glaxosmithkline Plc | Asthma | Details | |
Mepolizumab biosimilar (CTTQ Pharma) | Phase 1 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Hypereosinophilic Syndrome; Vasculitis; Nasal Polyps; Asthma; Eosinophilic Granuloma; Sinusitis | Details | |
Mepolizumab biosimilar(Bio Thera Solutions) | Phase 1 Clinical | Bio-Thera Solutions Ltd | Autoimmune Diseases; Nasal Polyps; Sinusitis | Details | |
SHR-1703 | SHR-1703 | Phase 2 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd, Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd | Asthma | Details |
Recombinant anti-IL-5 humanized monoclonal antibody (Shanghai CP Guojian) | 610 | Phase 2 Clinical | Shanghai Cp Guojian Pharmaceutical Co Ltd | Autoimmune Diseases; Asthma | Details |
Depemokimab | GSK-294; GSK3511294; GSK294; GSK-3511294 | Phase 3 Clinical | Glaxosmithkline Plc | Hypereosinophilic Syndrome; Churg-Strauss Syndrome; Nasal Polyps; Vasculitis; Asthma; Eosinophilic Granuloma; Sinusitis | Details |
This web search service is supported by Google Inc.